DUBLIN, Calif., Oct. 14, 2013 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc., a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, today announced four presentations of developmental and collaboration programs will be made at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Oct. 20 and 21, in Boston.
| SGI-110 | Abstract # A256 | |
| Poster Presentation | Sunday, Oct. 20 | 12:30 - 7:30 p.m. EDT |
| Improved Antitumor Activity by Sequencing SGI-110 with CTLA-4 Blockade in a Syngenic Mouse Model | ||
| XIAP | Abstract #A55 | |
| Poster Presentation | Sunday, Oct. 20 | 12:30 - 7:30 p.m. EDT |
| Potent, dual cIAP1/XIAP antagonists induce apoptosis in a melanoma stem cell population | ||
| LEE011 | Abstract #PR02 | |
| Proffered Paper Session | Sunday, Oct. 20 | 5:45 – 6 p.m. EDT |
| Abstract #B264 | ||
| Novartis Poster Presentation | Monday, Oct. 21 | 12:30 – 3 p.m. & 6:30 – 7:30 p.m. EDT |
| LEE011- An orally bioavailable, selective small molecule inhibitor of CDK4/6: Reactivating Rb in cancer | ||
| LEE011 | Abstract #A276 | |
| Novartis Poster Presentation | Sunday, Oct. 20 | 12:30 - 3 p.m. & 6:30 – 7:30 p.m. EDT |
| Phase 1 multicenter, open label, dose-escalation study of LEE011, an oral inhibitor of cyclin-dependent kinase 4/6, in patients with advanced solid tumors or lymphomas | ||
Select posters will be made available for viewing on the Astex website http://astx.com/pipeline/publications/.
About Astex Pharmaceuticals
Astex Pharmaceuticals is dedicated to the discovery and development of novel small molecule therapeutics with a focus on oncology. Astex is developing a proprietary pipeline of novel therapies and is creating de-risked products for collaborations with leading pharmaceutical companies. Astex Pharmaceuticals developed DACOGEN® (decitabine) for Injection and receives significant royalties on global sales.
For more information about Astex Pharmaceuticals, Inc., please visit http://www.astx.com.